Tevogen Bio Holdings Inc (TVGN)

$0.92 -0.08 (-8.24%)
Market Cap 189.06M
Revenue (ttm) 0.00
Net Income (ttm) -70,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.16
Volume 613,771
Avg Vol 2,154,322
Day's Range N/A - N/A
Shares Out 175.05M
Stochastic %K 0%
Beta -1.07
Analysts Strong Buy
Price Target $4.20

Latest News on TVGN

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

Mar 26, 2025, 3:12 PM EDT - 9 days ago

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Mar 25, 2025, 1:11 PM EDT - 10 days ago

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Mar 10, 2025, 12:40 PM EDT - 25 days ago

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

Mar 7, 2025, 4:09 PM EST - 27 days ago

Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

Mar 4, 2025, 1:52 PM EST - 4 weeks ago

Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Mar 3, 2025, 12:52 PM EST - 4 weeks ago

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Feb 28, 2025, 1:17 PM EST - 5 weeks ago

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Feb 21, 2025, 3:28 PM EST - 5 weeks ago

Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Feb 14, 2025, 6:31 PM EST - 6 weeks ago

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Feb 14, 2025, 1:16 PM EST - 7 weeks ago

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Feb 14, 2025, 11:52 AM EST - 7 weeks ago

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Feb 13, 2025, 4:34 PM EST - 7 weeks ago

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Feb 10, 2025, 5:30 PM EST - 7 weeks ago

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure

Feb 7, 2025, 2:56 PM EST - 7 weeks ago

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Jan 28, 2025, 3:49 PM EST - 2 months ago

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

Jan 27, 2025, 2:24 PM EST - 2 months ago

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Jan 24, 2025, 5:34 PM EST - 2 months ago

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Jan 23, 2025, 7:53 PM EST - 2 months ago

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Dec 26, 2024, 12:21 PM EST - 3 months ago

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 9:38 AM EST - 3 months ago

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Dec 19, 2024, 8:30 AM EST - 3 months ago

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound

Dec 18, 2024, 2:29 AM EST - 3 months ago

Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 1:32 PM EST - 3 months ago

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 3:13 PM EST - 4 months ago

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Dec 5, 2024, 11:03 AM EST - 4 months ago

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy

Nov 26, 2024, 8:05 AM EST - 4 months ago

Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Nov 21, 2024, 3:59 PM EST - 4 months ago

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Nov 19, 2024, 4:50 PM EST - 4 months ago

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Nov 14, 2024, 5:00 PM EST - 5 months ago

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Nov 14, 2024, 3:49 PM EST - 5 months ago

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Nov 8, 2024, 3:36 PM EST - 5 months ago

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Nov 5, 2024, 9:27 AM EST - 5 months ago

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Nov 4, 2024, 2:36 PM EST - 5 months ago

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Oct 31, 2024, 10:54 AM EDT - 5 months ago

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Oct 29, 2024, 3:28 PM EDT - 5 months ago

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million

Oct 29, 2024, 2:38 PM EDT - 5 months ago

Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million

Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

Oct 29, 2024, 12:43 PM EDT - 5 months ago

Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

Oct 25, 2024, 5:34 PM EDT - 5 months ago

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

Oct 23, 2024, 8:35 AM EDT - 5 months ago

Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week

Oct 22, 2024, 2:30 PM EDT - 5 months ago

Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week

Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Oct 21, 2024, 3:58 PM EDT - 5 months ago

Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

Oct 21, 2024, 1:56 PM EDT - 5 months ago

Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

Oct 18, 2024, 10:46 PM EDT - 5 months ago

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company's Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?

Oct 17, 2024, 11:57 AM EDT - 6 months ago

Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Oct 17, 2024, 9:32 AM EDT - 6 months ago

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion

Oct 17, 2024, 7:54 AM EDT - 6 months ago

Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

Oct 15, 2024, 2:30 PM EDT - 6 months ago

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

Oct 15, 2024, 11:36 AM EDT - 6 months ago

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

Tevogen CEO Reaffirms the Company's Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

Oct 14, 2024, 6:43 PM EDT - 6 months ago

Tevogen CEO Reaffirms the Company's Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

Oct 11, 2024, 3:59 PM EDT - 6 months ago

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024